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This study examined the prevalence of co-morbid age-related eye disease and symptoms
of depression and anxiety in late life, and the relative roles of visual function and
disease in explaining symptoms of depression and anxiety. A community-based sample
of 662 individuals aged over 70 years was recruited through the electoral roll. Vision
was measured using a battery of tests including high and low contrast visual acuity,
contrast sensitivity, motion sensitivity, stereoacuity, Useful Field of View, and visual
fields. Depression and anxiety symptoms were measured using the Goldberg scales.
The prevalence of self-reported eye disease [cataract, glaucoma, or age-related macular
degeneration (AMD)] in the sample was 43.4%, with 7.7% reporting more than one form of
ocular pathology. Of those with no eye disease, 3.7% had clinically significant depressive
symptoms. This rate was 6.7% among cataract patients, 4.3% among those with
glaucoma, and 10.5% for AMD. Generalized linear models adjusting for demographics,
general health, treatment, and disability examined self-reported eye disease and visual
function as correlates of depression and anxiety. Depressive symptoms were associated
with cataract only, AMD, comorbid eye diseases and reduced low contrast visual acuity.
Anxiety was significantly associated with self-reported cataract, and reduced low contrast
visual acuity, motion sensitivity and contrast sensitivity. We found no evidence for elevated
rates of depressive or anxiety symptoms associated with self-reported glaucoma. The
results support previous findings of high rates of depression and anxiety in cataract
and AMD, and in addition show that mood and anxiety are associated with objective
measures of visual function independently of self-reported eye disease. The findings have
implications for the assessment and treatment of mental health in the context of late-life
visual impairment.
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INTRODUCTION
Age-related eye disease and associated visual impairment is esti-
mated to affect over 372 million older adults globally, or 27.8% of
older adults (World Health Organization, 2012), and this number
is expected to rise with projected increases in the aging pop-
ulation (Ruiz-Moreno et al., 2007). Visual impairment and the
consequent disability and loss of quality of life in this age group
significantly impacts mental health (Lotery et al., 2007). Although
the rate of depression increases with age, it is 1.25–2.92 times
higher for older adults with vision impairment (Hayman et al.,
2007; Noran et al., 2009; Li et al., 2011), and age-related eye dis-
eases such as cataract (Fagerstrom, 1994; McGwin et al., 2003;
Freeman et al., 2009), glaucoma (Wilson et al., 2002; Mabuchi
et al., 2012; Tosini et al., 2012) and macular degeneration (Brody
et al., 2001; Casten et al., 2004; Tolman et al., 2005; Mathew et al.,
2011). In comparison, less is known about the rates of anxiety
in older adults with visual impairment (Evans et al., 2007; Li
et al., 2011). In the context of eye disease, both depression and
anxiety present significant impediments to patient recovery and
rehabilitation (Tolman et al., 2005; Walker et al., 2006), increase
levels of disability (Brody et al., 2001; Banerjee et al., 2008), and
ultimately represent a social and economic health burden on the
community Lotery et al., 2007; World Health Organization, 2012.
Thus, a clear understanding of the contributors to depression and
anxiety in older adults with visual impairment has implications
for treatment and public health.
Currently, there is a lack of data comparing the rate of depres-
sion across different eye diseases in late life. Most studies that
have examined depression in age-related eye diseases have either
focused on a single pathology (Fagerstrom, 1994; Brody et al.,
2001; McGwin et al., 2003; Freeman et al., 2009; Mathew et al.,
2011; Mabuchi et al., 2012), or vision impairment without identi-
fying the eye disease causing the visual loss (Hayman et al., 2007;
Li et al., 2011), or have compared common eye diseases with-
out adjusting for level of vision impairment (Horowitz et al.,
2005; Ruiz-Moreno et al., 2007). Because the prognosis, treat-
ment options and impact on vision vary considerably across
the common eye pathologies of cataract, glaucoma and macular
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degeneration (Voleti and Hubschman, 2013), it is expected that
patients’ outlook and the rate and severity of depression will also
vary with disease type. For example, age-related macular degener-
ation (AMD), the leading cause of irreversible visual loss in older
adults, affects central vision due to damage at the macular region,
and has a poorer prognosis compared to reversible eye condi-
tions such as cataract. This loss of central vision greatly impairs
hobbies, close work, reading and recognizing faces (Casten and
Rovner, 2008), with significant impacts on quality of life, inde-
pendence and mood (Cruess et al., 2007). In contrast, glaucoma
often has an insidious onset, primarily affecting peripheral vision,
such that its impact on functional activities may not be apparent
until quite advanced (Wilson et al., 2002; Tosini et al., 2012; Voleti
and Hubschman, 2013). Furthermore, unlike cataract and glau-
coma, current treatment options for AMD are limited, and meth-
ods for slowing progression have modest success rates (Voleti
and Hubschman, 2013). Consequently, much of the literature has
focused on depression in AMD compared to other eye diseases.
The rate of co-morbidity of major depression and AMD is
high (Brody et al., 2006; Rovner et al., 2007; Ruiz-Moreno et al.,
2007; Sun et al., 2007; Banerjee et al., 2008), and up to a third
of patients with AMD display sub-clinical depression. Even sub-
clinical depressive symptoms in AMD are associated with levels
of disability comparable to that of patients with AMD and major
depression (Horowitz et al., 2005; Rovner et al., 2006). A few stud-
ies have failed to find increased rates of depression in AMD (Sun
et al., 2007). However, many studies have not adjusted for the
association between severity of visual impairment and depression
(Horowitz et al., 2005; Ruiz-Moreno et al., 2007; Banerjee et al.,
2008) or comorbid eye conditions (Rovner et al., 2006), or have
used selected clinical samples that may not be representative of
the general AMD population (Tolman et al., 2005; Banerjee et al.,
2008). The relationship between AMD and depression is likely to
be a complex interaction between the disease, visual loss, quality
of life, disability and comorbidity (Hawkins, 2001; Freeman et al.,
2009; Mathew et al., 2011).
While little is known about the biological links between ocu-
lar pathology and mood and anxiety, there is some evidence
that reduced absorption of light due to retinal damage in AMD
and also glaucoma may lead to disturbed synthesis of melatonin,
which in turn increases the risk of sleep disturbance, depression,
and anxiety (Tosini et al., 2012). In addition, chronic conditions
such as diabetes and heart disease are known to be risk factors
for the development of AMD, cataract and glaucoma (Lotery
et al., 2007; Casten and Rovner, 2008) and are also independently
associated with depression (Horowitz et al., 2005). Dementia is
also associated with depression (Lyketsos et al., 2002) and also
vision problems as a result of neuro-degeneration (Trick and
Silverman, 1991). Thus, comorbid conditions, type of ARED and
level of visual impairment need to be considered separately when
explaining depression or anxiety in AREDs.
Depression in eye-disease has also been examined in relation to
treatment. Several studies have examined the impact of cataract
surgery on depression (McGwin et al., 2003; Mitsonis et al.,
2006; Walker et al., 2006; Freeman et al., 2009; Meuleners et al.,
2013) and anxiety (Mitsonis et al., 2006; Meuleners et al., 2013).
Depressive symptoms in cataract patients awaiting surgery are
higher in those with poorer visual acuity in the eye to be operated
on (Freeman et al., 2009). However, whether these depressive
symptoms abate after surgery is unclear (McGwin et al., 2003;
Mitsonis et al., 2006). Evidence for the relationship between glau-
coma and depression or anxiety is mixed, with some reports of
significantly higher prevalence relative to healthy controls, and
others indicating no relationship after adjusting for health condi-
tions (Wilson et al., 2002; Tosini et al., 2012). Nevertheless, there
is a suggestion that anti-glaucoma drugs may increase the risk of
depression (Tosini et al., 2012; Voleti and Hubschman, 2013).
These aforementioned variations in eye disease with respect to
prognosis, biology, comorbid conditions and treatment, all high-
light the issue that different eye diseases may have varying links
with depression and anxiety and that these inter-relationships
warrant further investigation. This may enable identification of
individuals at risk of poorer mental health associated with eye
disease (Casten and Rovner, 2008). In the present study, we
investigated the prevalence of self-reported cataract, glaucoma
and AMD and their associations with depression and anxiety
symptoms. We also examined whether objective measures of
functionally relevant visual abilities such as visual acuity, contrast
sensitivity, visual fields, and motion perception were associated
with symptoms of depression and anxiety independently of self-
reported ocular disease. The findings have implications for iden-
tification of at-risk older adults with specific eye disease to enable
better-targeted prevention and treatments.
METHODS
PARTICIPANTS
A community-based sample of 750 individuals over the age of
70 years residing in the Brisbane and Sydney metropolitan areas
(Australia) was recruited through the electoral roll for a study
on prevention of injury in older persons. In Australia, voting
is compulsory and therefore, all members of the community
who are eligible to vote are registered on the electoral roll. The
response rates for the Brisbane and Sydney sites were 18.84 and
28.56%, respectively. Participants were recruited into the study
if they were living independently without mobility aids, and
were aged between 70 and 95 years. Participants were excluded
if their MMSE score was below 24, suggesting cognitive impair-
ment or dementia. Of this sample, 662 participants provided
complete data on the outcome variable—the Goldberg Anxiety
and Depression (GAD) scale and were included in subsequent
analyses. Participants attended two laboratory-based sessions that
included visual, cognitive, and sensorimotor assessments. The
study received approval by the UNSW and QUTHuman Research
Ethics Committees.
MEASURES
Vision tests
Visual Acuity. Visual acuity was measured binocularly using a
high and low contrast Bailey-Lovie logMAR chart (Bailey and
Lovie, 1976) with participants’ usual distance corrective lenses,
where applicable, with the chart positioned at a distance of 3.2m
under standard illumination levels. Participants were instructed
to guess letters, even when they were unsure, until a full line of let-
ters was incorrectly read. Visual acuity was scored letter-by-letter
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and visual acuity expressed in Snellen notatation as well as
the logarithm of the minimum angle of resolution (logMAR).
Mild visual impairment was defined as 20/40 to 20/60 (logMAR
0.3–0.5), moderate as 20/80 to 20/160 (logMAR 0.6–0.9) and
severe is 20/200 or worse (logMAR of 1.0 or greater). Give the
reference for this definition.
Melbourne Edge Test (MET). Contrast sensitivity was measured
binocularly using the paper version of the Melbourne Edge Test
(MET) (Verbaken and Johnston, 1986) at a working distance of
40 cm and standard illumination levels. Participants wore their
corrective lenses for reading where necessary. The MET is a
four alternative forced-choice edge detection test which measures
contrast sensitivity at around 3 c/◦ (Haymes and Chen, 2004).
The lowest contrast edge correctly identified was recorded as the
participant’s contrast sensitivity in decibels (dB).
Visual Fields. Automated static visual fields were measured
binocularly using the Esterman protocol on the Humphrey
Field Analyzer (HFAII M750, Carl Zeiss Meditec, Dublin, CA).
Participants wore a working distance len correction as appropri-
ate. The Esterman Efficiency Score (percentage of points seen)
was recorded.
Frisby Stereotest. Near stereopsis was assessed using the Frisby
stereotest (Clement Larke International Ltd., London, UK). The
test consists of three transparent plates of different thicknesses
which present targets at different levels of depth disparity, rang-
ing from 600 to 15 s of arc depending on the plate and testing
distance. Testing was conducted using standard protocols and the
level of stereoacuity presented in secs of arc.
Useful Field of View Test (UFOV). The speed of visual informa-
tion processing and visual-spatial attention were measured using
the commercially available version of the Useful Field of View
(UFOV) test, which is PC based and linked to a touch screen
(17 in) for participant responses (Edwards et al., 2006). The first
subtest requires the participant to identify a central target (out-
line of a car or truck) presented on a computer monitor within
a central fixation box. The second subtest, which measures pro-
cessing speed for a divided attention task, involves identification
of the central target and simultaneous localization of a peripheral
target (outline of a car), presented at one of eight radial locations.
The third subtest included these two tasks as well as presentation
of peripheral visual distractors that are triangles of the same size
and luminance as the peripheral target car. Scores for each subtest
are expressed as the display duration, in ms, at which the partici-
pant performed accurately on 75% of trials. Thus, scores for each
subtest can range from 16 to 500ms. The UFOV score represents
the sum of the three subtest scores.
Visual Motion perception threshold. Participants’ threshold for
perceiving the direction of central visual motion was measured
using a computer-based random dot stimulus test (Wood et al.,
2008). Participants were seated 3.2m from the computer mon-
itor under low light conditions. Computer generated random
dot kinematograms were presented which consist of a pattern
of randomly arranged high density black and white dots (or
visual noise) a portion of which were coherently displaced in one
direction (left, right, up or down). The direction and amount
of displacement of the dots within the random dot display was
varied successively over multiple trials such that the direction
of movement became increasingly difficult to determine. The
displacement threshold Dmin expressed as log of visual angle
represented the smallest displacement for which the participant
could determine the direction of motion.
Eye-Disease
The presence of eye-disease was obtained via self-report.
Participants indicated their history of eye disease by selecting
responses to the following question: “Do/Did you have any of the
following eye-related problems? (Tick all that apply).” Response
options included cataract, glaucoma, macular degeneration, as
well as the eye (right, left or both) affected.
Self-completed questionnaire
Participants completed a questionnaire that provided informa-
tion on demographics: age, gender, education, source of income,
accommodation, history of general medical conditions (stroke,
TIA, diabetes, heart disease, arthritis, high blood pressure,
peripheral vascular disease), medications, and level of assis-
tance required for complex and self-care activities of daily liv-
ing (ADL/IADLs) such as shopping, cooking, washing clothes,
and dressing. Participants taking antidepressants were catego-
rized based on responses to medication questions. Participants
also provided data on whether they had undergone surgery
for cataract extraction. Levels of anxiety and depression were
measured using the 18 questions of the Goldberg Anxiety and
Depression Scales (GADS) (Goldberg et al., 1988). The total score
for each scale was used as the outcome variables in statistical anal-
yses. Participants also undertook theMMSE (Folstein et al., 1975)
as a screening measure for general cognitive impairment.
STATISTICAL ANALYSIS
All 662 participants had complete data for the following variables:
age, gender, Mini-Mental status exam (MMSE) score, housing,
self-reported myopia, presbyopia, visual field loss, congenital
monocular blindness, as well as objective monocular measures
of visual acuity under high contrast and low contrast. Data were
missing for <5% of cases for years of education, income source,
MET score, Frisby stereogram, and general medical conditions.
Data for 10% of cases was missing for the visual motion thresh-
old variable, and 39% of cases lacked data for the Esterman visual
field score. In order to retain the full sample for analysis, miss-
ing variables were imputed using the Multiple Imputation in
IBMSPSS Version 21. A missing value analysis indicated that data
was not missing at random across the variables [Little’s MCAR
test: χ2(185) = 702.53, p < 0.0001]. A Multiple Imputation was
conducted using a model with all of the variables of interest as
well as self-reported hearing impairment, body mass index, and
general health conditions.
Separate analyses were conducted to examine anxiety and
depression as correlates of vision function and eye disease. The
total GAD score was also modeled separately as recent studies
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have questioned the capacity of GAD scales for differentiating
depression from anxiety in older adults (Koloski et al., 2013). For
each analysis, the respective GAD scale was used as a continu-
ous outcome variable. Because the outcome variables were highly
skewed and non-normally distributed we used a generalized lin-
ear model with the log link function and a Poisson distribution.
The independent variables in each model included the self-
reported eye disease categories, MET score, Frisby stereotest, aver-
age visual acuity (for the two eyes) for high contrast and average
visual acuity under low contrast (logMAR units), Esterman visual
field score, the motion sensitivity threshold (log degrees/second),
and performance on the UFOV subtests. Covariates included in
the model were age, gender, years of education, income source
and accommodation type, MMSE score, the number of ADLs for
which help was required, the number of general health condi-
tions, self-reported myopia, long-sightedness, visual field loss and
congenital monocular blindness, cataract surgery and antidepres-
sant medications. The models also controlled for comorbid anx-
iety and depression. Goodness of fit statistics indicated that the
Poisson with log link model produced a better model fit (Akaike
Information Criterion: 1688.90) than the normal model with
identity link (linear regression) (AIC: 2385.36). Bonferroni cor-
rection for multiple comparisons were conducted where relevant
(α level = 0.0125).
RESULTS
The prevalence of any self-reported eye disease in the sample
was 43.4%. Including those with comorbidity, the prevalence of
self-reported cataract in our sample was 36.4%, glaucoma was
9.1%, and the prevalence of self-reported macular degeneration
in the sample was 6.0%. Participants reporting comorbid AREDs
accounted for 7.7% of the sample. Due to the small numbers of
participants reporting both AMD and glaucoma (n = 4), cataract
and AMD (n = 14) and triple comorbidity (n = 3) these groups
were combined with those reporting both cataract and glaucoma
(n = 30) to form the “Comorbid eye disease” category (n = 51).
The mean number of depressive symptoms on the GAD dif-
fered significantly across the self-reported eye disease categories
–where AMD-only and the Comorbid group displayed nearly
twice the mean number of depressive symptoms [Means = 1.11
(1.76) and 0.96 (1.91), respectively] relative to the no eye disease
group [Mean = 0.53 (1.16)] (Table 1). There was however, no
significant difference in the mean number of anxiety symptoms
across the eye disease categories. The GAD scales were origi-
nally validated in a young population (Goldberg et al., 1988)
and recent data from Australian samples suggest that the aver-
age number of reported symptoms of depression and anxiety
differ with gender and age cohort (Jorm et al., 2005). Based
on these norms for older Australian adults (Jorm et al., 2005),
above average levels of depression were relatively rare in our
study sample (3.7% for no eye disease). Although this rate was
higher in the AMD only group (10.5%), this was not a statistically
reliable difference across the groups. Similarly, although the self-
reported eye disease groups showed higher rates of above average
anxiety (e.g., 10.5% in AMD and 11.8% in comorbid group
vs. 8.3% in reference group) this was not a reliable difference
(Table 1).
Bivariate correlationss between the eye disease and vision
variables and the depression and anxiety scales indicated that
depressive symptoms were significantly correlated with eye dis-
ease category (Spearman’s ρ = 0.102, p < 0.01), high contrast
visual acuity (ρ = 0.212, p < 0.01), low contrast visual acuity
(ρ = 0.235, p < 0.01) and visual motion sensitivity threshold
(ρ = 0.211, p < 0.01). Anxiety symptoms were also significantly
correlated with self-reported eye disease category (ρ = 0.08, p <
0.05), high contrast visual acuity (ρ = 0.205, p < 0.01), low
contrast visual acuity (ρ = 0.215, p < 0.01) and visual motion
sensitivity threshold (ρ = 0.190, p < 0.01).
A generalized linear model was used to examine eye disease
and vision as correlates of depressive symptoms. The model con-
trolled for age, gender, income source, accommodation type,
the number of comorbid general health conditions, and level of
assistance required for IADL/ADLs. Table 2 displays the unstan-
dardized coefficients (B) and odds ratios (OR) for each inde-
pendent variable pooled across the five imputed data sets. The
main model effects indicated eye disease was significantly asso-
ciated with depressive symptoms [Wald χ2(5) = 13.52, p < 0.01].
Relative to the reference group reporting no eye disease, higher
levels of depressive symptoms were associated with reporting
cataract only [B = 0.33(0.13), p < 0.0125; OR = 1.40(CI 95%:
1.07–1.81)], and comorbid eye conditions [B = 0.60(0.19), p <
0.01; OR = 1.82 (CI 95%:1.25–2.65)]. Those reporting AMD
only also reported elevated levels of depressive symptoms, but
this failed to reach significance after correction for multiple
comparisons [B = 0.51(0.25), p < 0.05; OR = 1.66 (CI 95%:
1.02–2.70)]. Independent of the type of eye disease, depressive
symptoms were also associated with poor low contrast visual acu-
ity [B = 0.04(0.017), p < 0.05; OR = 1.06 (CI 95%: 1.0–1.08)].
Results for the vision and eye-disease as correlates of anx-
iety indicated that there was a main effect for eye disease
[Wald χ2(5) = 10.89, p < 0.05]. Table 3 shows that relative
to those reporting no eye disease, self-reported cataract only
[B = 0.34(0.12), p < 0.01; OR = 1.41 (CI 95%: 1.11–1.79)] was
significantly associated with depressive symptoms. Visual func-
tion also correlated with anxiety. Reduced low contrast visual
acuity was associated with increased anxiety symptoms [B =
0.041(0.018), p < 0.05; OR = 1.04 (CI 95%: 1.00–1.08)] as
was edge contrast sensitivity [B = 0.06(0.027), p < 0.05; OR =
1.06 (CI 95%: 1.01–1.12)] and visual motion perception [B =
0.16(0.026), p < 0.001; OR = 1.17 (CI 95%: 1.11–1.23)].
Analysis of the association between vision, eye disease, and
total GAD score produced similar results. There was a main
effect for eye disease [Wald χ2(5) = 25.43, p < 0.001]. Table 4
shows that relative to those reporting no eye disease, high
GAD scores were associated with self-reported cataract only
[B = 0.36(0.09), p < 0.001; OR = 1.43 (CI 95%: 1.20–1.71)],
AMD only [B = 0.50(0.18), p < 0.01; OR = 1.66 (CI 95%:
1.17–2.33)],and comorbid eye disease [B = 0.44(0.13), p < 0.01;
OR = 1.54 (CI 95%: 1.19–1.71)]. In addition, high GAD scores
were associated with reduced edge contrast sensitivity [B =
0.06(0.02), p < 0.01; OR = 1.06 (CI 95%: 1.02–1.10)], low con-
trast visual acuity [B = 0.05 (0.01), p < 0.01; OR = 1.04 (CI
95%: 1.02–1.09)] and motion sensitivity thresholds [B = 0.11
(0.02), p < 0.001; OR = 1.12 (CI 95%: 1.07–1.17)].
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Table 1 | Demographic and health characteristics of the sample as a function of eye disease.
No eye disease Single eye disease Co-morbid eye Diseases p†
Cataract Glaucoma Macular degeneration
N 375 194 23 19 51
Age (SD) 75.98 (4.36) 77.57 (4.5) 76.22 (2.89) 75.63 (4.25) 79.94 (4.91) **
Sex (% males) 53.3% 42.3% 65.2% 42.1% 52.9%
Years of education 11.54 (3.91) 11.43 (4.04) 11.78 (3.49) 11.63 (3.24) 11.06 (3.9)
Mini-mental state exam 27.7 (1.79) 27.84 (1.67) 28.09 (1.7) 27.89 (1.73) 27.69 (1.6)
INCOME SOURCE
Pension 57.4% 55.0% 56.5% 42.1% 58.0%
Self-funded retiree 39.3% 44.5% 43.5% 57.9% 40.0%
Employed 3.3% 0.5% 0.0% 0.0% 2.0%
HOUSING TYPE
Own house or unit 93.6% 92.8% 91.3% 100.0% 90.0%
Hostel/boarding/granny flat 6.1% 6.7% 8.7% 0.0% 0.0%
Nursing home 0.3% 0.5% 0.0% 0.0%
GAD depression 0.53 (1.16) 0.83 (1.55) 0.91 (1.41) 1.11 (1.76) 0.96 (1.91) *
GAD anxiety 0.68 (1.36) 0.92 (1.6) 0.65 (1.46) 1.05 (2.17) 0.94 (1.76)
Depression above average 3.70% 6.70% 4.30% 10.50% 7.80%
Anxiety above average 8.30% 10.80% 8.70% 10.50% 11.8%
Anti-depressant medication 8.50% 7.20% 4.30% 5.30% 9.80%
General health—SF-36 74.48 (16.34) 67.82 (20.0) 74.52 (10.97) 71.42 (19.2) 67.18 (17.9) **
Mental health—SF-36 84.63 (14.47) 81.56 (15.1) 80.17 (11.8) 82.95 (14.04) 80.71 (15.6)
Physical functioning—SF-36 77.27 (19.44) 72.67 (20.98) 77.39 (14.84) 73.42 (22.24) 67.35 (22.3) **
Stroke/TIA 6.4% 12.4% 26.1% 5.3% 13.7% **
Diabetes 5.3% 7.2% 17.4% 5.3% 15.7% **
Heart disease 21.1% 31.4% 17.4% 10.5% 31.4% *
Hypertension 38.7% 46.9% 52.2% 47.4% 35.3%
Requires assistance with ADLs/IADLs 4.3% 9.8% 4.3% 5.3% 9.8%
Number of general health conditions 1.11 (0.05) 1.49 (0.08) 1.52 (0.27) 1.05 (0.19) 1.45 (1.12) **
Cataract surgery 3.5% 57.2% 13.0% 10.5% 52.9% **
*p < 0.05; **p < 0.01; Note: †omnibus ANOVA or Chi-squared tests.
Table 2 | Association between eye disease and visual function and depressive symptoms.
Variable B(SE ) CI 95% OR
Comorbid eye diseases 0.60 (0.19) (0.23, 0.98) 1.82 (1.25, 2.65)**
AMD only 0.51 (0.25) (0.02, 1.0) 1.66 (1.02, 2.70)†
Glaucoma only 0.37 (0.25) (−0.12, 0.86) 1.44 (0.88, 2.36)
Cataract only 0.33 (0.13) (0.07, 0.60) 1.40 (1.07, 1.81)*
Frisby stereogram 0 (0) (0.003, −0.001) 1.00 (0.999, 1)
Melbourne Edge Test 0.02 (0.027) (−0.03, 0.07) 1.01 (0.97, 1.05)
Esterman visual fields 0.003 (0.018) (−0.04, 0.05) 1.00 (0.96, 1.05)
Visual acuity high contrast 0.069 (0.04) (−0.016, 0.153) 1.07 (0.98, 1.17)
Visual acuity low contrast 0.04 (0.017) (0.01, 0.07) 1.04 (1.0, 1.08)*
UFOV 0.000 (0.001) (0.001, 0.006) 1.003 (1.001, 1.006)
Motion sensitivity threshold 0.06 (0.035) (−0.01, 0.13) 1.06 (0.99, 1.14)
* p < 0.05; **p < 0.01; Results Bonferroni corrected for multiple comparisons †near significant.
DISCUSSION
We examined the prevalence of self-reported comorbid eye dis-
ease, visual function status and depressive and anxiety symptoms
in a community based sample of 662 older adults. Consistent
with prior studies, we found that depressive symptoms were
higher amongst participants reporting eye-disease relative to
those who did not. Specific measures of vision function also
significantly correlated with depressive symptoms, and this
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Table 3 | Association between eye disease and visual function and anxiety symptoms.
Variable B(SE ) CI 95% OR
Comorbid eye diseases 0.35 (0.19) (−0.06, 0.71) 1.42 (0.98, 2.04)
AMD only 0.46 (0.247) (−0.023, 0.95) 1.59 (0.98, 2.58)
Glaucoma only −0.03 (0.28) (−0.58, 0.53) 0.93 (0.56, 1.70)
Cataract only 0.34 (0.12) (0.10, 0.59) 1.41 (1.11, 1.79)**
Frisby stereogram 0 (0) (0.003, −0.001) 1.00 (0.999, 1)
Melbourne Edge Test 0.06 (0.027) (0.01, 0.11) 1.06 (1.01, 1.12)*
Esterman visual fields −0.001 (0.021) (−0.052, 0.05) 1.00 (0.95, 1.05)
Visual acuity high contrast −0.027 (0.05) (−0.14, 0.08) 0.97 (0.87, 1.09)
Visual acuity low contrast 0.041 (0.018) (0.01, 0.08) 1.04 (1.00, 1.08)*
UFOV 0.00 (0.0003) (0.00, 0.001) 1.00(1.00, 1.00)
Motion sensitivity threshold 0.16 (0.026) (0.10, 0.21) 1.17 (1.11, 1.23)**
*p < 0.05; **p < 0.01; Results Bonferroni corrected for multiple comparisons.
Table 4 | Association between eye disease and visual function and total GAD score.
Variable B (SE ) CI 95% OR
Comorbid eye diseases 0.44 (0.13) (0.18–0.69) 1.54 (1.19, 2.00)**
AMD only 0.50 (0.18) (0.16–0.85) 1.66 (1.17, 2.33)**
Glaucoma only 0.04 (0.19) (−0.33–0.41) 1.04 (0.72, 1.51)
Cataract only 0.36 (0.09) (0.18–0.54) 1.43 (1.20, 1.71)**
Frisby stereogram 0.00 (0.00) (−0.001–0.00) 1.00 (0.99, 1.00)
Melbourne Edge Test 0.06 (0.02) (0.02–0.09) 1.06 (1.02, 1.10)**
Esterman visual fields 0.004 (0.02) (−0.05–0.05) 1.00 (0.96–1.05)
Visual acuity high contrast 0.04 (0.04) (−0.06–0.12) 1.04 (0.95, 1.13)
Visual acuity low contrast 0.05 (0.01) (0.02–0.09) 1.04 (1.02, 1.09)**
UFOV 0.00 (0.00) (−0.00–0.001) 1.00 (0.999–1.00)
Motion sensitivity threshold 0.112 (0.02) (0.07–0.16) 1.12 (1.07–1.17)**
**p < 0.01; Results Bonferroni corrected for multiple comparisons.
was apparent after controlling for age, socio-demographic fac-
tors, general health, anti-depressant medication, comorbid anx-
iety, treatment for cataracts, IADL/ADLs and self-reported eye
disease.
In relation to self-reported eye disease, higher depressive
symptoms were associated with reporting only cataract [OR =
1.40 (1.07–1.81)], comorbid eye disease [OR = 1.82 (1.25–2.65)]
and a near-significant trend was apparent for AMD [OR =
1.66(1.02–2.70)]. These findings support previous reports of
cataract as a predictor of depression (Fagerstrom, 1994; McGwin
et al., 2003; Freeman et al., 2009) and additionally show that the
relationship is independent of measures of visual function and is
evident after adjusting for a range of health, demographic, treat-
ment and socio-economic variables. Few studies have examined
the relation between depression and multiple eye diseases. Our
findings indicate individuals reporting multiple eye diseases are
more likely to report higher levels of depressive symptoms inde-
pendent of visual function and reporting a single eye disease. The
results also revealed a trend for elevated levels of depression in
those reporting AMD only—consistent with prior reports (Brody
et al., 2001; Casten et al., 2004; Tolman et al., 2005; Mathew et al.,
2011). The lack of any significant association between the pres-
ence of glaucoma and depressive symptoms in our data is also
consistent with the few studies that have looked for and failed
to find an association, after controlling for confounders (Wilson
et al., 2002; Tosini et al., 2012). However, our data were only self-
reported and glaucoma is known to be under-diagnosed in the
population (Quigley, 1996).
In relation to symptoms of anxiety, higher levels of anx-
iety were associated with self-reported cataract alone [OR =
1.41(1.11–1.79)]. There is mixed evidence regarding the asso-
ciation between anxiety and eye-disease (Mabuchi et al., 2012;
Tosini et al., 2012) or anxiety and visual impairment (Evans
et al., 2007), and our study represents the only investiga-
tion of anxiety symptoms in relation to a range of eye
disease through self-report as well as objective measures of
visual function. Studies on the rate of anxiety and depres-
sion in cataract patients have largely focused around surgery,
whereas the present findings relate to a non-surgerical con-
text, suggesting that participants who are aware of hav-
ing cataract may experience greater levels of generalized
anxiety.
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Our data reveal that objective indices of visual impairment
and functional vision are associated with depressive symptoms
and anxiety symptoms independent of self-reported eye disease.
Specifically, poorer low contrast visual acuity increased the odds
of depressive and anxious symptomatology by 4%. Poor edge con-
trast sensitivity also related to anxiety symptoms, and reduced
motion sensitivity increased the odds of anxiety symptoms by
17%. Although small, these odds were statistically reliable. Several
previous studies have reported a significant correlation between
visual acuity and depression, independent of disease (Brody et al.,
2001; Evans et al., 2007), however, most have used visual acuity
at only one level of contrast (Brody et al., 2001; Rovner et al.,
2006; Evans et al., 2007; Tosini et al., 2012), or visual acuity under
both low and high contrast but not eye disease (Hayman et al.,
2007). Nevertheless, most conclude that self-reported functional
consequences of vision impairment maymediate the link between
depression and objective measures of impairment (Brody et al.,
2001; Rovner et al., 2006; Evans et al., 2007; Hayman et al.,
2007; Freeman et al., 2009; Tosini et al., 2012). Although we
did not use a measure of self-rated functional difficulties spe-
cific to vision as other studies had (e.g., VF-14) we found the
need for assistance with IADLs/ADLs was more common in the
eye-disease groups (4.3–13.3%) than amongst controls (4.3%),
and our analysis adjusted for this. Further, we included objective
measures of functional vision via the UFOV. This test is sen-
sitive to age-related changes in vision, information processing
speed and visual attention (Ball and Owsley, 1993), and is pre-
dictive of both falls risk (Vance et al., 2006) and driving capacity
in older adults (Ball and Owsley, 1991). Interestingly, however,
we found performance on the UFOV was not associated with
depression or anxiety symptoms after adjusting for the other
variables.
In the present study, we did not conduct a comprehen-
sive cognitive assessment and used MMSE scores to control
for significant cognitive impairment. Dementia is known to
contribute to both depression and visual problems in older
adults. Neuro-degeneration underlying dementia can affect the
cortical and subcortical pathways of the visual system, and
result in impaired visual function—including motion perception
(Trick and Silverman, 1991; Iseri et al., 2006). In our study we
excluded those with significant cognitive impairment, but may
have retained individuals with mild cognitive impairment (MCI).
Potential effects of MCI on visual function are not known, and
post-mortem and neuroimaging data indicate the visual cortex
is relatively spared of early neuro-pathological changes in MCI
patients (Guillozet et al., 2003; Kempainen et al., 2007). Thus,
based on current evidence, we expect that a direct effect of
dementia-related neuropathology on visual problems would have
been low. Nevertheless, depression is a neuropsychiatric symptom
of both MCI and dementia (Lyketsos et al., 2002), thus, MCI may
have independently contributed to depressive symptoms in some
of our sample.
The relationship between specific vision measures and depres-
sive and anxious symptomatology may reflect their effect on
particular important activities such as reading, driving, and hob-
bies requiring close work (Tabrett and Latham, 2011). In our
sample, poor low contrast visual acuity and reduced edge contrast
sensitivity were associated with higher depression scores and
also anxiety scores. Deficits in both of these domains could sig-
nificantly impair daily function from activities such as reading
through to mobility and driving. Further, reduced visual motion
sensitivity may also impair judgment of environmental hazards
and thereby increase anxiety related to mobility and falls. In
addition to indirect effects on mood and anxiety via the impact
of vision on function, the relationship may also include direct
effects. Recent reports suggest that contrast sensitivity may be
reduced in clinically depressed individuals, independent of any
effect of mood on self-reported visual function (Bubl et al.,
2013), and that even in the non-depressed, greater depressive
symptoms are correlated with lower contrast sensitivity (Bubl
et al., 2013). The authors further reported that contrast sensitiv-
ity normalizes with treatment of depression (Bubl et al., 2012).
While the latter findings have not been substantiated in older
adults with vision impairment, it suggests there may be biolog-
ical pathways between mood and vision that are independent
of eye-disease pathology and which may need to be consid-
ered when treating adults with comorbid depression and eye
disease.
The present work has several limitations. A significant limi-
tation is that eye-disease was obtained by self-report. Reported
rates of glaucoma, cataract, and AMD are thus, biased by par-
ticipant recall and awareness of often subtle changes in the early
stages of the disease, particularly in the case of glaucoma (Wilson
et al., 2002; Tosini et al., 2012; Voleti and Hubschman, 2013).
We also did not have sufficient data to control for duration of
diagnosis, which others have found may modify the relation-
ship. As the study was cross-sectional in design, the reported
relationships cannot reveal whether visual function and eye-
disease predicted the development of depression and anxiety in
this cohort, and longitudinal data is required to confirm such
a causative relationship. Strengths of the study include the use
of a relatively large community-based sample of participants
with a range of eye diseases, making the findings more gener-
alizable to the population. We also used objective measures of
functional vision that are unlikely to be biased by low mood
as would self-reported functional vision. Although the rate of
eye disease was higher in the study sample relative to Australian
population estimates (AIHW), the rates of depression and anx-
iety reported in our study are comparable to other population-
based studies of eye-disease [4.6% in controls, 12% cataract,
15.1% for AMD (Evans et al., 2007); controls 3.0%, ARED
4.7% (Li et al., 2011)]; and anxiety [controls 4.3%; ARED 6.5%
(Li et al., 2011)].
To conclude, the present study provides significant insights
into comorbid depression and anxiety in older adults with self-
reported eye-disease. The findings indicate that self-reported eye
diseases as well as specific vision measures need to be consid-
ered when treating and managing older adults with eye disease.
Primary care practitioners should consider eye disease and vision
function in the context of depression and anxiety in older adults.
The high contrast visual acuity chart available to most primary
care practitioners do not assess low contrast visual acuity (Woods
and Wood, 1995) that may affect everyday function and be
associated with mood and anxiety in the older patient.
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